A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's annual report on Form 20-F for the year ended December 31, 2012 (Annual Report), which is available at www.sedar.com or at www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

CONTACT: Investors         Jodi Regts         Director, Investor Relations         Phone: 604-419-3234         Email: jregts@tekmirapharm.com                  Media         David Ryan         Longview Communications Inc.         Phone: 416-649-8007         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Tekmira Pharmaceuticals (TKMR) Weak On High Volume

Tekmira Pharmaceuticals (TKMR): Today's Weak On High Volume Stock

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst